<DOC>
	<DOCNO>NCT01363557</DOCNO>
	<brief_summary>Multicentre randomise ( 1:1 ) trial assess efficacy whole brain radiotherapy addition Gefitinib management brain metastasis lung cancer patient mutate EGFR .</brief_summary>
	<brief_title>Assess Efficacy Whole Brain Radiation Therapy Lung Cancer Patients With Brain Metastasis</brief_title>
	<detailed_description>Lung cancer patient newly diagnose CNS metastasis with- least one brain lesion measure &gt; 1 cm long dimension - eligible surgery stereotactic radio-surgeryOpen-label , multicentre , national , randomise ( 1:1 ) phase II trialArm A : WBRT Concurrent Gefitinib follow Gefitinib Maintenance Arm B : Gefitinib</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>Patients must sign write informed consent form prior study specific screening procedure 18 year old KPS ≥ 50 % Histologically confirm adenocarcinoma lung Activating mutation EGFR Newly diagnose CNS metastasis progression least one measurable lesion brain ( defined lesion &gt; 1 cm T1weighted contrast enhance MRI ) Patients could enter study regardless previous treatment ( included chemotherapy ) metastatic extracranial disease , except TKI . No steroid stable decrease dose steroid least 5 day MRI evaluation . Adequate hematologic , liver renal function : neutrophil count ≥ 1.5 x 109/L ; platelet ≥ 100 x 109/L ; Hb ≥ 9 g/Dl ; Total bilirubin &lt; 1.5 x ULN ; AST ALT &lt; 2.5 x ULN ( &lt; 5 x ULN patient liver metastasis ) ; Serum creatinine ≤ 1.5 x ULN Creatinine clearance ≥ 50 mL/min Prior treatment brain metastasis WBRT TKI Patient eligible radiosurgery surgical resection Contre indication radiotherapy Leptomeningeal disease Previous history cancer ( curatively treat basal squamous cell carcinoma skin and/or insitu carcinoma cervix ) within 5 year study entry Prior treatment Gefitinib TKI Pregnant breast feeding woman Women intact uterus ( unless amenorrhoeic last 24 month ) use effective mean contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Randomized</keyword>
	<keyword>Brain Radiation Therapy</keyword>
	<keyword>Lung Cancer</keyword>
	<keyword>Brain Metastasis</keyword>
	<keyword>Gefitinib</keyword>
</DOC>